All sectors · Built to order
Executive and technical compensation benchmark for radiopharma, ADC, cell and gene therapy, CDMO and CRO
What leaders and technical specialists are paid across a set of companies, how their teams are structured, and where hiring signals point next.
What you receive
- A written report that answers the questions agreed at scoping, with a clear verdict on each
- The read from the leaders running these businesses, gathered through our search work and attributed by role
- A data workbook with the underlying tables, so your team can filter, check and reuse the work
- A source register with the source and date behind each key fact
What can be in scope
- Compensation by role, level, function, location and company stage
- Leadership team structures and reporting lines across the peer set
- Bench depth and where leaders came from
- Hiring signals by company and role
- Time-to-fill and exposure for critical seats
Standard biotech benchmarks under-price leaders in radiopharma, ADC and advanced therapies, where licences, containment and scale-up experience are scarce. This benchmark reads compensation, team structure and hiring signals across the set of companies you choose to compare against.
For pay bands and levelling for your own roles, see Compensation and Organisation Benchmarks. This analysis is built for comparing across companies: a peer set, a portfolio or a sector.
Who commissions it
- Investors benchmarking leadership across a portfolio or before an investment
- Boards and remuneration committees setting packages
- Leadership and HR teams planning a build-out
- Corporate development teams assessing a target's team
The questions it answers
- What do comparable companies pay their leaders and technical specialists, in base, bonus and equity?
- How do pay and structure differ by modality, function, location and company stage?
- How are leadership teams in the peer set structured, and how deep is the bench in each function?
- Which companies are hiring, for which roles, and what does that signal about their plans?
- Which seats are exposed against the next milestone, and how long would they take to fill?
What you are buying access to
A proprietary intelligence base
Producers, facilities, pipelines, transactions, compensation and dated market signals across radiopharma, ADC, cell and gene therapy, CDMO and CRO, built and maintained by ProGen.
Access to the people who run it
Our executive search work puts us in conversation with the leaders of these businesses every week. Their read on the market goes into your answer.
Built around your decision
Scoped to the call in front of you: an investment, a partner, a supplier or a market. Every key fact sourced and dated.
How it works
Tell us your question
Choose an analysis below or describe your own. The more specific the decision, the sharper the scope.
Scope and quotation within one business day
We reply with the questions we will answer, what is in and out of scope, the timeline and a fixed quotation.
Your answer, built to stand up
A written report with a clear verdict, the read from the leaders in the space, a data workbook and a source register.
Request this analysis
Tell us the decision and the questions behind it. Within one business day you have the scope, the timeline and a fixed quotation.
Other analyses
- The Isotope Production MapEvery medical isotope producer, mapped by route and capacity. Refreshed quarterly.
- Ac-225 Supply and Demand OutlookWhen does Ac-225 stop being scarce, and who wins when it does?
- Isotope Supply Security AssessmentOne reactor, one target, one supplier. How exposed is your programme?
